Meeting
2013 ASCO Annual Meeting
Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.
Authors
Yongjun Cha
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Yongjun Cha , Yu Jung Kim , Tae Min Kim , Seung Hong Choi , Se-Hoon Lee , Dong-Wan Kim , Chul-Kee Park , Il Han Kim , Jee Hyun Kim , Eunhee Kim , Byung Se Choi , Chae-yong Kim , In Ah Kim , Dae Seog Heo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2098)
DOI
10.1200/jco.2013.31.15_suppl.2098
Abstract #
2098
Poster Bd #
8F
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
First Author: Sylvia Christine Kurz
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia
First Author: Ana Oaknin